LOTTE Biologics Achieves Major Manufacturing Deal Before Songdo Plant Launch

LOTTE Biologics, co-led by CEOs James Park and Yoo-yeol Shin, has secured a pivotal commercial manufacturing agreement with a global pharmaceutical company, marking a significant milestone as it prepares for the launch of its Songdo Plant 1. This agreement positions LOTTE Biologics as a leader in the biopharmaceutical manufacturing sector and underscores the company's robust commercial strategy.

The partnership entails LOTTE Biologics providing integrated drug substance and drug product manufacturing services for key products within the customer's portfolio, with commercial production aimed to commence in 2027. By locking in these commitments while the facility is still under construction, this deal not only highlights customer confidence in the technical skills and execution capabilities of LOTTE Biologics but also establishes a strong foundation for future growth.

The Songdo Plant 1 is designed to meet the rising demands in global biopharmaceutical manufacturing, featuring cutting-edge production infrastructure, sophisticated automation, and expansive cold-chain warehousing, all designed to ensure efficiency, reliability, and quality in operations. The broader Songdo Bio Campus aims for a total production capacity of 360,000 liters across three separate plants, with Plant 1 alone anticipated to deliver 120,000 liters through eight 15,000-liter stainless-steel bioreactors.

This facility will complement LOTTE Biologics' existing Syracuse Bio Campus in New York, which boasts over 20 years of manufacturing experience and has successfully supported more than 62 regulatory approvals. Importantly, the recent FDA inspection of the Syracuse site resulted in zero observations, a testament to its operational excellence. The integration of the Syracuse and Songdo sites is aimed at providing customers with operational flexibility, consistent quality standards, and greater resilience across the supply chain.

As pharmaceutical companies increasingly seek reliable manufacturing partners with proven execution capabilities and diversified supply chains, LOTTE Biologics positions itself as an attractive option in the global biologics manufacturing landscape. This recent agreement is a tangible move toward achieving their long-term growth ambitions and reflects their commitment to translating strategic investments into concrete commercial engagements.

"This agreement not only validates our growth strategies but also demonstrates our customers' trust in LOTTE Biologics as a partner, not just in manufacturing capacity but in overall quality and reliability," stated James Park, Co-CEO of LOTTE Biologics. "We are committed to building a globally integrated platform that marries the proven experience of Syracuse with the innovative infrastructure of Songdo. Our ultimate goal is to facilitate the success of our partners and ensure that life-changing medicines reach patients around the world efficiently and effectively."

In summary, this major agreement serves as a pivot point for LOTTE Biologics, aligning their operational capabilities with market demands and positioning the company as a leading Contract Development and Manufacturing Organization (CDMO) by 2030.

Topics Business Technology)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.